Clinical trials: Hemophagocytic Syndrome
Lymphohistiocytosis, Hemophagocytic
Prospective Single-Arm Clinical Trial of GO Regimen for HLH.
This study aims to investigate the efficacy and safety of Golidocitinib(GO) monotherapy in the treatment of hemophagocytic lymphohistiocytosis.
- Trial name
- NCT07339345
- Testing
- Golidocitinib
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Beijing Friendship Hospital
Hemophagocytic Lymphohistiocytosis
Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004
Without therapy HLH is often fatal, and often rapidly fatal. The treatment protocol HLH-94 has improved survival markedly as compared to the survival earlier. We now aim to improve survival further.
- Trial name
- NCT00426101
- Testing
- Dexamethasone, Etoposide, Cyclosporin
- Where
- Sweden
- Volunteers
- 368 people
- Sponsor
- Karolinska University Hospital
Hemophagocytic Lymphohistiocytoses
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH
Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening condition characterized by uncontrolled hyperinflammation which may develop on the background of several clinical conditions (e.g.
- Trial name
- NCT03985423
- Testing
- Emapalumab-Lzsg
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Swedish Orphan Biovitrum
Hemophagocytic Lymphohistiocytosis, Epstein-Barr Virus
Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement
EBV-HLH is a rare disease with high mortality, especially for those with intestinal involvement. In order to reduce disease burden and improve survival of these patients, we conduct a prospective observational study to explore…
- Conditions
- Hemophagocytic Lymphohistiocytosis, Epstein-Barr Virus, Bowel Resection
- Trial name
- NCT06131489
- Testing
- Segmental bowel resection combined with the DEP regimen
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Friendship Hospital
COVID
Establishing a COVID-19 Prospective Cohort for Identification of Secondary HLH
SARS-CoV2 has become a pandemic disease putting an enormous burden on health care systems around the world. A considerable amount of patients require intensive care treatment for Covid-19 associated pneumonia.
- Trial name
- COVIDHLH (NCT04347460)
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Technical University of Munich
Safety and Efficacy
Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH
ENKTL is a highly aggressive non-Hodgkin lymphoma closely related to EBV infection，and advanced patients often suffer from hemophagocytic lymphohistiocytosis (HLH).
- Trial name
- NCT05008666
- Testing
- Sintilimab, Chidamide, Azacitidine
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Sun Yat-sen University
Hemophagocytic Lymphohistiocytosis
L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLH
This study aimed to investigate the efficacy and safety of L-DEP (L-Asparaginasum, liposomal doxorubicin, etoposide and methylprednisolone) together with PD-1 antibody as an treatment for relapse/refractory EBV associated…
- Trial name
- NCT05315336
- Testing
- L-DEP and PD-1 antibody
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Beijing Friendship Hospital
HLH, Hemophagocytic Lymphohistiocytoses
Establishing a National Egyptian HLH Registry (NEHR)
Establishing a National Egyptian HLH Registry (NEHR)
- Trial name
- NEHR (NCT07800234)
- Where
- 2 sites in Egypt
- Volunteers
- 100 people
- Sponsor
- Ain Shams University
SCID, Omenn's Syndrome
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
This is a standard of care treatment guideline for allogeneic hematopoetic stem cell transplant (HSCT) in patients with primary immune deficiencies.
- Conditions
- SCID, Omenn's Syndrome, Reticular Dysgenesis, Wiskott-Aldrich Syndrome
- Trial name
- NCT01652092
- Testing
- Alemtuzumab 0.3 mg, Cyclophosphamide, Busulfan
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
PD-1 Antibody, Mixed Chimerism
PD-1 Antibody Improve Mixed Chimerism
PD-1/PD-L1 pathway play an important role in Inhibiting the function of antigen-specific CD8+T cells, thus matter a lot in immune escape.
- Trial name
- HLH (NCT04944511)
- Testing
- Toripalimab Injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Friendship Hospital
Primary Haemophagocytic Lymphohistiocytosis
Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic Lymphohistiocytosis
The purpose of this study is to assess the safety, tolerability and efficacy of a new drug aimed at controlling disease activity in patients diagnosed with primary haemophagocytic lymphohistiocytosis.
- Trial name
- NCT01818492
- Testing
- NI-0501
- Where
- 20 sites in United States, Germany and 4 more
- Volunteers
- 45 people
- Sponsor
- Swedish Orphan Biovitrum
Lymphohistiocytosis, Hemophagocytic, Secondary Hemophagocytic Lymphohistiocytosis
Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study
Background: Hemophagocytic lymphohistiocytosis (HLH) is a disease caused by disrupted immune function. People with HLH are prone to fevers and illnesses, which can be fatal.
- Conditions
- Lymphohistiocytosis, Hemophagocytic, Secondary Hemophagocytic Lymphohistiocytosis, Macrophage Activation Syndrome, Hyperinflammatory Syndromes
- Trial name
- NCT06339177
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lymphoma, Haemophagocytic Lymphohistiocytosis
Assessing the Presence of CT-DNA in Lymphoma Associated HLH
Haemophagocytic lymphohistiocytosis (HLH) is a rare life-threatening blood disease which causes severe inflammation with symptoms similar to severe sepsis. It is hard to diagnose.
- Trial name
- NCT05702502
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Nottingham University Hospitals NHS Trust
Hemophagocytic Lymphohistiocytosis, B Cell Lymphoma
Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma
For patients who met the inclusion criteria, treatment regimens were administered: Rituximab 375 mg/m², intravenously, once weekly for 4 weeks. Zanubrutinib 160 mg, orally, twice daily for 4 weeks.
- Trial name
- NCT07270835
- Testing
- Rituximab, Zanubrutinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Secondary Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection
Prospective Study of Immune Function and PD-1 Antibody Therapy Efficacy Predictors on CAEBV and EBV-HLH Patients
This prospective case-control study aims to evaluate the immune function and find PD-1 antibody efficacy predictors on Chronic Active Epstein-Barr Virus Infection and Epstein-Barr virus-associated hemophagocytic…
- Trial name
- NCT05841342
- Testing
- No intervention
- Where
- China
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Beijing Friendship Hospital
Familial Lymphohistiocytosis, Lymphohistiocytosis
Impact of Ultra-fast Genetic Diagnosis of Familial Lymphohistiocytosis on the Time to Bone Marrow Transplantation and Overall Survival
Familial lymphohistiocytosis (FHL) is a group of rare genetic diseases (around fifteen cases per year in France). The defect in T lymphocyte cytotoxicity resulting from this disease is responsible for hemophagocytic…
- Trial name
- LongRead-HLH (NCT07741747)
- Testing
- Third-generation sequencing
- Where
- France
- Volunteers
- 240 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Hemophagocytic Lymphohistiocytoses
Prospective Cohort for Adult Hemophagocytosis
This prospective study enrolls subjects who have clinical and laboratory manifestations related with hemophagocytic lymphohistiocytosis.
- Trial name
- NCT03117010
- Testing
- Steroids, Etoposide
- Where
- South Korea
- Volunteers
- 81 people
- Sponsor
- Samsung Medical Center
Hemophagocytic Syndrome
Establishment of an Early Warning Screening System for Hemophagocytic Lymphohistiocytosis a Multi-center, Prospective Study
Our three-step screening system uses commonly used clinical and laboratory parameters to effectively identify patients who may be at high risk of HLH, conduct etiology screening early for patients who meet the diagnostic criteria…
- Trial name
- NCT06614998
- Testing
- Patients diagnosed with HLH-94 should be treated as soon as possible
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma
CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene
Patients are being asked to participate in this study because they will be receiving a stem cell transplant as treatment for their disease.
- Conditions
- Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Myelodysplastic Syndrome, Chronic Myeloid Leukemia
- Trial name
- CASPALLO (NCT00710892)
- Testing
- Allodepleted T Cells
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Baylor College of Medicine
Hemophagocytic Syndrome
A Randomized Controlled Study of High-dose Cyclophosphamide Induction Therapy in Adult Patients With HLH
Adult secondary HLH involves tumors, autoimmune diseases and other causes in addition to infection,Infectious factors, theoretically need different treatment methods for different etiology.
- Trial name
- NCT05936086
- Testing
- Cytoxan, Etoposide, Dexamethasone
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- shifeng Lou